Portal de Periódicos da CAPES

Response to recombinant erythropoietin alpha, without the adjunct of granulocyte-colony stimulating factor, is associated with a longer survival in patients with transfusion-dependent myelodysplastic syndromes

2009; Elsevier BV; Volume: 34; Issue: 8 Linguagem: Inglês

10.1016/j.leukres.2009.10.022

1873-5835

Pellegrino Musto, Oreste Villani, Maria Carmen Martorelli, Giuseppe Pietrantuono, Roberto Guariglia, Giovanna Mansueto, Fiorella D’Auria, Vitina Grieco, Gabriella Bianchino, Anna Sparano, Antonia Zonno, Rosa Lerose, Grazia Sanpaolo, Antonietta Falcone,

Neutropenia and Cancer Infections

This was a retrospective, comparative study focused on the extended follow-up of 192 transfusion-dependent patients with myelodysplastic syndromes treated (n. 83) or not treated (n. 109) with recombinant erythropoietin alpha (r-EPO) as single agent during the course of their disease. The results supported the safety of this treatment in the long term and also showed a significant survival advantage (median 52 months vs. 31 months, p<0.0095) in responding patients as compared to non-responding ones or to subjects never treated with r-EPO. At multivariate analysis, response to r-EPO maintained an independent prognostic value on OS.